The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)
Information source: Yokohama City University Medical Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bone Density; Arthroplasty, Replacement, Hip
Intervention: alendronate, alfacalcidol (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Yokohama City University Medical Center
Summary
The purpose of this study is to evaluate whether alendronate and alfacalcidol are effective
on prosthetic or lumbar spine BMD after total hip arthroplasty.
Clinical Details
Official title: A Comparison of Alendronate vs. Alfacalcidol Medication for the Preservation of Bone Mineral Density Around the Femoral Implant and in the Lumbar Spine After a Total Hip Arthroplasty
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: DEXA QDR 2000, Hologic Co.
Eligibility
Minimum age: 44 Years.
Maximum age: 82 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- osteoarthritis of the hip
- patients after total hip arthroplasty
Exclusion Criteria:
- diseases related to bone metabolism
- patients taking drugs which affect bone metabolism
Locations and Contacts
Department of orthopaedic surgery, Yokohama City University, Yokohama, Kanagawa, Japan
Additional Information
Starting date: January 2006
Last updated: December 2, 2009
|
